|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07K 7/06 | (2006.01) |
| C07K 14/47 | (2006.01) | ||
| G01N 33/53 | (2006.01) |
| (11) | Number of the document | 2582714 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11727401.9 |
| Date of filing the European patent application | 2011-06-21 | |
| (97) | Date of publication of the European application | 2013-04-24 |
| (45) | Date of publication and mention of the grant of the patent | 2017-05-10 |
| (46) | Date of publication of the claims translation | 2017-08-25 |
| (86) | Number | PCT/EP2011/003074 |
| Date | 2011-06-21 |
| (87) | Number | WO 2011/160827 |
| Date | 2011-12-29 |
| (30) | Number | Date | Country code |
| PCT/EP2010/0037 | 2010-06-21 | WO |
| (72) |
BONNY, Christophe, CH
|
| (73) |
Xigen Inflammation Ltd.,
Arch. Makariou III 195 Neocleous House, 3030 Limassol,
CY
|
| (74) |
Marija LENKUTIENĖ,
Patentinių paslaugų centras, UAB, Jono Basanavičiaus g. 11/1, LT-03108 Vilnius,
LT
|
| (54) | Naujos JNK inhibuojančios molekulės |
| NOVEL JNK INHIBITOR MOLECULES |
| Payment date | Validity (years) | Amount | |
| 2018-11-08 | 8 | 277.50 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2019-06-21 |